Página 1 a partir de 29 resultados
Phototherapy is one of the mainstays of treatment for early mycosis fungoides (MF). The most common modalities are psoralen-UV-A (PUVA) and narrowband UV-B (NBUVB).To compare the efficacy and adverse effects of PUVA vs NBUVB in early-stage I Employing psoralen plus solar irradiation therapy in 20 patients with plaque psoriasis, improvement was noted in 55% of the patients. The overall improvement rate was however higher (95%) with coal tar plus solar irradiation treatment in the other group of 20 patients. In both groups, improvement
Thirty-eight patients with plaque-type psoriasis were enrolled in a double-blind psoralen plus ultraviolet A (PUVA) treatment study comparing the efficacy and side effects of 5-methoxypsoralen (5-MOP) and 8-methoxypsoralen (8-MOP). Patients treated with 8-MOP healed significantly faster than those
OBJECTIVE
To compare the efficacy of narrowband UV-B (TL-01) phototherapy with oral 8-methoxypsoralen photochemotherapy (8-MOP psoralen-UV-A [PUVA]) in patients with chronic plaque psoriasis (CPP).
METHODS
Open, randomized, controlled study.
METHODS
Phototherapy unit in a dermatology
BACKGROUND
Both bath psoralen plus ultraviolet A (PUVA) and oral PUVA with 8-methoxypsoralen (8-MOP) have been successfully used for the treatment of recalcitrant palmoplantar psoriasis. This trial was designed to assess the efficacy and side effects of the different treatment modalities in a
BACKGROUND
Bath-PUVA-photochemotherapy has become a useful alternative to oral PUVA therapy due to a number of advantages over systemic PUVA, for example, no ophthalmologic risk and nausea, and a lower cumulative UVA doses. However, its major disadvantage is the logistical requirement for bath tubs
5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo. In patients and volunteers, PUVA 5-methoxypsoralen causes a dose-related increase in cutaneous
Photochemotherapy with psoralen and long-wave ultraviolet light, so-called PUVA-treatment, is currently being evaluated in many dermatologic departments. Side effects such as nausea, pruritus and erythema are well known. Recently the development of acneiform eruptions was reported in a British
Trioxsalen (TMP) bath PUVA avoids the side effects of nausea and headache associated with oral 8-methoxypsoralen (8-MOP) treatment and allows shorter irradiation times that can be advantageous in some patients. However we noted that a number of patients developed unusual patterns of phototoxic
A clinical cooperative study involving 14 centers evaluated photochemotherapy (psoralen and high-intensity long-wave ultraviolet light [PUVA]) for psoriasis. Results from 465 patients treated with a PUVA-48 unit (equipped with 48 high-intensity UVA bulbs) and 110 patients treated with a PUVA-64 unit
BACKGROUND
Topical PUVA therapy has become a useful alternative for patients who cannot tolerate the systemic side effects of nausea and headache or are concerned about the ophthalmologic risk associated with oral PUVA therapy. However, there is no study to date on the systemic absorption of
We have used oral psoralen photochemotherapy (PUVA) to treat four patients with chronic graft-versus-host disease of the skin, oral mucosa, and liver, who had responded only partially to long-term immunosuppressive therapy (prednisolone, cyclosporine, azathioprine). PUVA therapy was delivered to the
Photochemotherapy is very effective for the treatment of skin diseases such as psoriasis, as well as for the prophylactic 'hardening' therapy of patients suffering from polymorphic light eruption. The photosensitizers most widely used for oral photochemotherapy are the furocoumarins
In an 8-week double-blind trial of sulfasalazine for the treatment of moderate-to-severe psoriasis, 23 and 27 patients received the active and placebo tablets, respectively. At the end of the double-blind phase, there were 17 assessable patients receiving sulfasalazine; 7 (41%) had marked
BACKGROUND
In recent years photopheresis, an extracorporeal form of photochemotherapy using psoralen and ultraviolet A irradiation of leucocytes, has been claimed to be an effective form of immunomodulation.
OBJECTIVE
To evaluate its effect in type 1 diabetes we performed a double blind, controlled